| Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide | Janssen Pharma | ||
| 800 mg/150 mg/ 200 mg/10 mg ; Tablets |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| SYMTUZA is a four-drug combination of darunavir (DRV), a human immunodeficiency virus (HIV-1) protease inhibitor, cobicistat (COBI), a CYP3A inhibitor, and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen for the treatment of HIV-1 infection in adults: • who have no prior antiretroviral treatment history or • who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. | |||
|
Yes
| |||
| Symtuza | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | **** *** | **** *** | *** ********* | **** *** | *** ********* | ******* | ******* | ******* ***** ********* ************ | ****** *** | ****** ******** ****** | ****** ******** ****** | *** ********* |
| ****** | *** ********* | ******* **** *** | ******* **** *** | *** ********* | *** ********* | *** ********* | ******* | ******* | ******* ***** ********* ************ | ****** *** | ****** ******** ****** | ****** ******** ****** | ****** ******** ****** |
| ****** ** ********** *** ********* ******** ** *,*-*********** *********** *********** | ******** ** *********** ********** ********* | ***************** ***** ** * *** ******** ********* | ******** ** *********** *********** ********* | ********** ** *************** ********** ** ************ | ***************** ***** ** * *** ******** ********* | ********* *********** ************ | ********* *********** ************ | *** ** ***** ******* ********* ** ******* *** ************** ** * ************** ***** | ************ *** ******* ** ******** *** | ******* *** ************* *** ********* ************** ****** | ******* *** ************* *** ********* ************** ****** | ******* *** ************* *** ********* ************** ****** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** / ********* | ***** **, **** | ******* ***** ********* ************ | ********* ******** | ******* **** **** *** *** **** |
| ****** | ** / ** | *** **, **** | ******* ***** ********* ************ | **** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|